Paul L. Berns

CEO

Board Member

Chairman

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Recorded roles and earnings-call appearances connecting this person to public companies.

NMRA

Current role

CEO, Board Member, Chairman

2020-01-01–present

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Neumora Therapeutics, Inc. (NMRA)	Chief Executive Officer	$700,000	$21,000	—	$3,326,181	$504,000	$11,280	$4,562,461
2024	Neumora Therapeutics, Inc. (NMRA)	Executive Chairman	$470,000	—	$3,094,488	$4,818,975	$253,800	$11,130	$8,648,393
2023	Neumora Therapeutics, Inc. (NMRA)	Executive Chairman	$537,500	$16,125	—	$6,922,080	$1,082,737	$11,826	$8,570,268
2022	Neumora Therapeutics, Inc. (NMRA)	Executive Chairman and former Chief Executive Officer	$570,000	—	—	$1,755,346	$308,798	$780	$2,634,924

Earnings-call appearances and filed executive appointments or departures, newest first.